Snowball logo
logo
BMXM

bioMérieux S.A

BMXMF • PINK
$99.90+$0.27  (0.27%)
Estimate
P/E
22
EPS
4.55
Beta
0.55
Growth
Revenue, YoY
3.14%
Net income, YoY
4.86%
FCF, YoY
532.95%
Dividends
Dividend yield
1.16%
Annual payout
$1.16
Next ex. div date
June 10, 27
Payout
13.83%
Div.growth, 5y
9%
Dividend growth streak
3 y
Div.rating
About the company
Ticker
BMXMF
ISIN
Country
France
Sector (GICS)
Healthcare
bioMérieux S.A. develops, manufactures, and markets in vitro diagnostic solutions for infectious diseases in France, Europe, Africa, the Middle East, North and South America, the Asia Pacific, and internationally. It operates through Clinical Applications and Industrial Applications segments. The company offers CHROMID RANGE, a chromogen culture media; air, surface, and water monitoring systems; BACT/ALERT VIRTUO, a blood sample culture system; BIOFIRE, a multiplex polymerase chain reaction system (PCR); BIOFIRE SPOTFIRE, a lowplex PCR point-of-care system; VITEK MS, a mass spectrometry system; VITEK 2, an automated identification and antimicrobial susceptibility testing (AST) system; API RANGE standardized ID strips; VITEK REVEAL, a rapid AST system; ETEST, a gradient method on culture media; BIOMERIEUX EPISEQ CS, a whole genome sequencing solution for epidemiologic monitoring; VIDAS, a specific marker of severe bacterial infections/sepsis; and Biomérieux vision suite, a software that provides information to support diagnosis and clinical decision making. It also provides culture media and associated instruments; ARGENE that provides PCR tests for diagnosing viral respiratory diseases; EMAG system and NUCLISENS extraction reagents for DNA and RNA extraction; GENE-UP and VERIFLOW for detection of microorganisms for the food industry; ETEST for manual measurement of minimum inhibitory concentration of an antibiotic; API and RAPIDEC CARBA NP for identification of bacteria and manual antimicrobial susceptibility testing; BIOBALL for quantitative microbiological quality control; CHEMUNEX, a microbiology instrument; ENDONEXT for detection of endotoxins; TEMPO for fluorescence counting of bacteria; and Hybiome, a CLIA technology, as well as lab consultancy service and training modules. The company was formerly known as B-D Mérieux. The company was founded in 1963 and is headquartered in Marcy-l'Étoile, France. bioMérieux S.A. operates as a subsidiary of Institut Mérieux SA.

Frequently asked questions

What sector does bioMérieux S.A (BMXMF) operate in?

bioMérieux S.A belongs to the Healthcare sector and operates in the Diagnostics & Research industry.

What is bioMérieux S.A (BMXMF) current stock price?

As of the latest data, bioMérieux S.A stock price is $99.90, with a previous close of $99.63. bioMérieux S.A gained $0.27 in the last trading session, representing a 0.27% increase.

What is bioMérieux S.A (BMXMF) current market capitalization?

bioMérieux S.A market cap is approximately 11.76 billion.

What is bioMérieux S.A (BMXMF) Earnings Per Share (EPS)?

The trailing EPS is $4.55.

What is bioMérieux S.A (BMXMF) Price-to-Earnings (P/E) ratio?

bioMérieux S.A current P/E ratio is 21.96.

What is bioMérieux S.A (BMXMF) EBITDA?

bioMérieux S.A EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is 440.54 million.

Does bioMérieux S.A (BMXMF) pay dividends?

Yes. bioMérieux S.A pays annual dividends with an annualized yield of 1.16% and an estimated annual payout of $1.16 per share.

When is the next ex-dividend date for bioMérieux S.A (BMXMF)?

The next ex-dividend date is scheduled for June 10, 2027.

What is bioMérieux S.A (BMXMF) beta (volatility) score?

bioMérieux S.A has a beta of 0.550, indicating lower volatility than the overall market.